Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease

Clin Exp Nephrol. 2022 Dec;26(12):1242-1243. doi: 10.1007/s10157-022-02260-7. Epub 2022 Aug 1.

Authors

Kei Matsumoto^#¹, Hiroyuki Ueda^#¹, Nobuo Tsuboi^#², Takashi Yokoo¹

Affiliations

¹ Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, Japan.
² Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, Japan. tsuboi-n@jikei.ac.jp.

^# Contributed equally.

PMID: 35913494
DOI: 10.1007/s10157-022-02260-7

No abstract available

Keywords: Chronic kidney disease; Dapagliflozin; Glomerular filtration rate; Hyperfiltration.

Publication types

Letter

MeSH terms

Benzhydryl Compounds / therapeutic use
Diabetes Mellitus, Type 2* / drug therapy
Diabetic Nephropathies* / diagnosis
Diabetic Nephropathies* / drug therapy
Glomerular Filtration Rate
Glucosides / therapeutic use
Humans
Kidney
Renal Insufficiency, Chronic* / diagnosis
Renal Insufficiency, Chronic* / drug therapy

Substances

dapagliflozin
Glucosides
Benzhydryl Compounds